The Monash Partners Comprehensive Cancer Consortium (MPCCC) is recognised as the Cancer and Blood Diseases Theme. MPCCC is a strategic alliance of health service and research organisations working in partnership to improve cancer outcomes through integrated, collaborative and innovative research, service improvement and clinical care programs.
MPCCC comprises a network of partner hospitals and associated health services that deliver care for people with all types of cancers, integrated with a research network of more than 500 academic, clinical and health services researchers. The MPCCC provides a single portal for improvement in the diagnosis and management of cancer and blood diseases for the people of South and East Victoria, treating over 19,000 patients each year with around 80,000 episodes of care.
Our goal is to improve patient experience and outcomes across the cancer care continuum, through world-class research and quality improvement.
This ambition will be realised by linking our expertise across basic, translational, clinical, health service, population health and epidemiological research with the service delivery expertise of our clinical partners.
The Cancer and Blood Diseases Theme aims to:
- Design and deliver a holistic and equitable cancer research and improvement agenda that addresses the needs of people affected by cancer
- Build capacity for world-class innovations in cancer treatment by linking discovery, pre-clinical and clinical research
- Drive improvements in cancer care through innovative research and improvement
- Use data wisely and strategically to inform priorities and measure outcomes
- Establish and maintain strategic collaborations to align cancer research and improvement activities with cancer, health and research policy agendas, and link activities with available resources
- Establish and maintain appropriate governance and processes to lead and promote a world-class cancer research and improvement agenda.
Cancer and Blood Diseases Theme Leaders
The Theme is led by Dr Peter Briggs, Professor Gail Risbridger, Professor Eva Segelov and Professor John Zalcberg.
Dr Peter Briggs was Head of Medical Oncology at Monash Health since 2000, Clinical Director of the…
Southern Melbourne Integrated Cancer Service (SMICS) since 2011, Peter was also instrumental in the establishment of the MPCCC. Peter is active in clinical research across a variety of malignancies. His latest interests include design of investigator led protocols for clinical trials in lung cancer and collaborations to include predictive clinical tools and biomarker exploration. Peter is currently on extended leave.
Professor Gail Risbridger is Research Director at the Monash Partners Comprehensive Cancer Consortium and played an integral role both in the establishment of the consortium and Monash Partners.
She is a National Health and Medical Research Council (NHMRC) research fellow and a career academic and researcher with more than 20 years’ experience in prostate cancer research and men’s health.
Professor Eva Segelov is Director of Oncology at Monash Health and Professor of Oncology in the Department of Medicine, Monash University, and has accepted the role of Acting Clinical Director of SMICs and MPCCC while Peter Briggs is on extended leave.
Previously, Eva worked as a clinical academic and senior staff specialist in medical oncology at the University of New South Wales. Her clinical focus has been in the management of patients with breast, upper and lower gastrointestinal cancer and neuroendocrine tumours, while Eva’s research interests are in clinical trials and associated translational research.
Professor John Zalcberg is Professor of Cancer Research in the School of Public Health and Preventive Medicine at Monash University.
Prior to this appointment he served as Director of the Division of Cancer Medicine at the Peter MacCallum Centre in Melbourne for 17 years.
Our Steering Committee
Supporting the Theme leaders is an internationally respected team of multi-disciplinary cancer and blood disease specialists who are committed to the Theme’s vision and dedicated to delivering its programs. Members of the MPCCC Cancer and Blood Diseases Theme Steering Committee include:
In addition to the Theme Executive and Steering Committee, a Governance Group has been appointed to provide financial authority and prioritisation, review deliverables and ensure policy alignment across the partnership.
MPCCC Research Programs
The Cancer and Blood Diseases Theme’s research is delivered through three ‘Collaborative Platforms’, which reflect our commitment to patient-centred clinical care. For further details, see below.
USING DATA AS A FOUNDATION FOR HIGH-QUALITY CANCER CARE
Flagship Project 1:
Establishing a Centre for Cancer Outcomes Excellence
The MPCCC will leverage its world-class expertise in the collection and use of clinical outcomes data, to drive patient-centred optimal cancer care.
The premise of this project is that innovation in cancer care must be informed by robust, local data about patients, the treatment and care they have received, the outcomes of that care, and by the active engagement of clinician leaders at a local level to interpret the data and to lead improvement efforts. Data will be used locally and MPCCC-wide, informing patient-centred quality improvement activities aligned with the Optimal Care Pathways (hyperlink), and contributing to state-wide reviews of variation.
Flagship Project 2:
Enhancing clinical pathways through real-time collection and reporting of PROMs and PREMs
Patient Reported Outcome Measures (PROMs) capture an individuals’ assessment of their health or wellbeing without interpretation by a clinician or other people. Patient Reported Experience Measures (PREMs) are tools and instruments that capture the overall patient experience of health care, typically focusing on patient satisfaction scores.
This project will develop and test the real-time collection and use of PROMs and PREMs to enhance point-of-care adoption of clinical pathways and referrals and improve health care equity for disadvantaged groups.
Automating collection of PROMs will provide real-time feedback to health professionals about the clinical and supportive care needs of their patients, allowing them to address needs as they arise. Collection of PREMs will support improvements in local health service planning to optimise patient experience. The collection of PROMs and PREMs will also support the collection and analysis of data at a population level to inform future health service planning and quality improvement activity.
IMPROVING CANCER OUTCOMES THROUGH INNOVATIVE RESEARCH
Flagship Project 1:
Using precision medicine to overcome resistance to cancer therapy
This project will focus on patients who have acquired or innate resistance to therapy, including targeted and immunotherapies.
Fresh therapy-resistant tumour specimens will be used for molecular and immunome profiling studies as well as to generate patient-derived tumour models for evaluating therapy responses.
This information will be integrated into clinical management via an MPCCC Precision Medicine Tumour Board.
Flagship Project 2:
Innovating to improve clinical trials access and recruitment: MPCCC Tele-Trials
The Tele-Trials initiative aims to help patients living outside the city to gain access to clinical trials, and in turn, access to cutting-edge cancer treatment.
This pilot program focuses specifically on patients in Gippsland and on the Mornington Peninsula, but is also set to benefit the state more widely by driving investment from industry sectors, and technological advances in healthcare.
INCREASING CAPACITY THROUGH INNOVATIVE MODELS OF SHARED CARE
Flagship Project 1:
Developing, testing and implementing service delivery improvements
Traditional models of specialist-driven cancer care place a high burden on acute care settings. They can also present a significant challenge for patients, particularly those from non-metropolitan settings, who need to travel for treatment and follow-up appointments.
Our MPCCC Shared Cancer Care project will trial and assess a shared approach between specialist and primary care practitioners to care for cancer patients receiving treatment and follow-up support.
Flagship Project 2:
Improving supportive care for people with cancer through an integrated collaborative program
Clinical depression, anxiety and adjustment disorder are highly prevalent in cancer patients and survivors. If undetected and/or under-treated, they can adversely impact quality of life and coping with disease burden.
This project will develop and evaluate an innovative shared care model for delivery of supportive care in people with cancer and their carers by bringing together community-based clinical psychologists with GPs and hospital-based psychiatrists with expertise in oncology (psycho-oncologists).
The overall aim of the project is to build the capacity of health services across the MPCCC to address the supportive care needs of people affected by cancer and their carers, and to provide a model that can be implemented more broadly across Victoria.
 Shared care is defined as the joint participation of primary care and specialty care health professionals in the planned delivery of care, informed by an adequate education program and information exchange over and above routine referral notices.